Parabolic Drugs gets certified by European Union

• Certification of European Union for the Cephalosporin’s manufacturing facility in Punjab
• This will boost company’s sales & expand presence in European, Canadian & Australian markets worth US$16.37 bn for the Cephalosporin range.

Parabolic Drugs Limited (PDL), a leading research based API manufacturer with stronghold in Antibiotic space and marking its presence in the Custom Synthesis and Contract manufacturing (CRAMS) segment today announced its certification of European Union for its Cephalasporin’s manufacturing facility in Derabassi, Punjab.

The 27 acre Cephalosporin API’s & intermediates manufacturing unit was inspected by German Auditors in April & found to be compliant with the Principles of GMP (EU-GMP – Part II) for Active substances.

The company has received approval for three of its molecules – namely, Cefuroxime Axetil, Cefpodoxime Proxetil and Cefixime Trihydrate. This will enable the company to sell its products into Europe, Canada & Australian markets, thus giving a boost to Company’s vision of building its business in regulated markets.

Commenting on the occasion, Mr. Vineet Gupta, Executive Director, Parabolic Drugs Ltd said “Parabolic already has a USFDA approval for selling one of its products in the US markets from its Panchkula facility. With this EU-GMP certification of its Derabassi facility, PDL has expanded its sales reach in the highly regulated markets and has positioned itself as a strong API company”.

About Parabolic Drugs Ltd
Parabolic Drugs Limited is one of the fast growing API (Active Pharmaceutical Ingredients) and API intermediate manufacturing and marketing company in the SME segment, with increasing international presence and a strong R&D foundation, based at Chandigarh, India. Commissioned in 1998, PDL has two fully functional, state of the art manufacturing units, a EU-GMP certified Unit based in Derabassi (Punjab) and a USFDA accredited manufacturing plant at Panchkula, (Haryana) respectively.

Parabolic Drugs also has an R&D and CRAMS facility at Barwala in Haryana and has  executed 8 custom synthesis contracts for global innovator and biotech companies since January 2010. It is also setting up a APi facility in Chachrauli, Punjab for manufacturing non-antibiotic products and has a pipeline of 20 non-antibiotic products. Parabolic closed sales of Rs. 559 crores for the financial year 2009- 2010 and has grown at a CAGR of 60% in the last five years.